Inactive Instrument

Press Releases ChemoCentryx, Inc.

Equities

CCXI

US16383L1061

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

CHEMOCENTRYX, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	22-10-20	AQ
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX	22-10-20	PR
CHEMOCENTRYX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	22-10-18	AQ
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings	22-10-17	GL
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings	22-10-17	GL
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting	22-10-05	GL
CHEMOCENTRYX, INC. : Other Events (form 8-K)	22-09-20	AQ
ChemoCentryx Announces TAVNEOS (avacopan) Presentations at Upcoming Medical Conferences	22-08-25	AQ
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences	22-08-24	GL
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call	22-08-09	GL
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call	22-08-09	AQ
CHEMOCENTRYX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-08	AQ
CHEMOCENTRYX, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-08-04	AQ
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH	22-08-04	PR
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022	22-08-02	GL
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022	22-08-02	GL
ChemoCentryx : Announces Appointment of Jennifer L. Herron to Board as Independent Director - Form 8-K	22-07-05	PU
CHEMOCENTRYX, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-07-05	AQ
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director	22-07-05	GL
CHEMOCENTRYX, INC. : Change in Directors or Principal Officers (form 8-K)	22-06-09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ChemoCentryx, Inc.

Equities

CCXI

US16383L1061

Press Releases

Filters